Storey

Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes

Retrieved on: 
月曜日, 6月 3, 2024
Morgan Stanley, Attention, Telephone, Varick Street, Prospectus, Citigroup, BofA Securities, J. P. Morgan, Sale, Vanderbilt Avenue, Security (finance), TD Securities, U.S. Bancorp, Broadridge Financial Solutions, Storey, TEL

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”):

Key Points: 
  • NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”):
    The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd.
  • The offering is expected to close on June 10, 2024, subject to the satisfaction of customary closing conditions.
  • Royalty Pharma intends to use the net proceeds from the Notes for general corporate purposes.
  • The Notes are being offered pursuant to an effective shelf registration statement that the Company filed with the Securities and Exchange Commission (the “SEC”).

Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million

Retrieved on: 
木曜日, 5月 9, 2024
Neurology, Mental Health, Health, Pharmaceutical, Clinical Trials, Sale, Agreement, Prospectus, Common, Post-traumatic stress disorder, Funding, Regulation D, Bipolar disorder, Security (finance), Form, Conversion, Common stock, Storey

The Preferred Shares will be senior to all other classes of preferred stock the Company has outstanding, as well as senior to the Company’s common stock (“Common Stock”).

Key Points: 
  • The Preferred Shares will be senior to all other classes of preferred stock the Company has outstanding, as well as senior to the Company’s common stock (“Common Stock”).
  • The Preferred Shares also has “full ratchet” price protection in the event the Company should issue securities at a lower price than the Conversion Price.
  • The Preferred Shares shall pay a dividend at an annual rate of 15%, which the Company shall pay, at the Investor’s election, either in cash or Preferred Shares.
  • A final prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC.

Absolute Security to Demonstrate Next Generation Cyber Resilience During RSA Conference 2024

Retrieved on: 
木曜日, 5月 2, 2024
Mobile, Wireless, Technology, Security, Other Technology, Software, Networks, Internet, Hardware, Data Management, Artificial Intelligence, Absolute, Complexity, Risk, Personal computer, AI, MSP, Trust, MSSP, OS, Platform as a service, Original equipment manufacturer, Intelligence, Storey, PC, Face, RSAC, Quarantine, RSA, Organization, Connect

Absolute Security , the leader in enterprise cyber resilience, today announced it will demonstrate the next-generation of enterprise cyber resilience during RSA Conference™ 2024.

Key Points: 
  • Absolute Security , the leader in enterprise cyber resilience, today announced it will demonstrate the next-generation of enterprise cyber resilience during RSA Conference™ 2024.
  • During the conference, CISOs and other security and risk professionals responsible for protecting their organizations against cyber disruptions and threats such as ransomware and unauthorized access are invited to hosted demonstrations of the Absolute Cyber Resilience Platform.
  • Most new customers have the Absolute Cyber Resilience Platform embedded in their endpoints, as it is pre-installed in the firmware of more than 600 million devices.
  • To learn more and see demos, visit Absolute Security during RSAC 2024 at the Hotel Zetta, Second Floor , Demo Room, San Francisco.

NuZee, Inc. Announces Completion of Private Placement of Convertible Note and Warrants

Retrieved on: 
木曜日, 5月 2, 2024
Sale, Coffee, Storey, Security (finance)

The private placement closed on May 2, 2024.

Key Points: 
  • The private placement closed on May 2, 2024.
  • Each purchaser of the convertible notes receives warrants to purchase 100% of the number of shares of common stock into which such purchaser's note is initially convertible.
  • The warrants will be immediately exercisable, have an exercise price of $1.322 per share and expire two years after issuance.
  • The transaction, including the conversion price of the convertible notes and the exercise price of the warrants, was priced pursuant to Nasdaq's "Minimum Price" requirements under Nasdaq Listing Rule 5635(d).

Axena Health receives two additional positive insurance coverage decisions for Leva

Retrieved on: 
木曜日, 4月 11, 2024
Medical Devices, Women, FDA, Health Technology, Health Insurance, Biotechnology, Health, Consumer, Pharmaceutical, UI, Urinary incontinence, Woman, BCBS, Food, Cigna, The Institute, Leva, MD, Highmark, Life, Pelvic floor, Female, Pelvic organ prolapse, Privacy, Incontinence, Overactive bladder, Storey, MBA, FACOG, Food and Drug Administration, HCPCS, Nursing

Both positive coverage decisions became effective on April 1, 2024.

Key Points: 
  • Both positive coverage decisions became effective on April 1, 2024.
  • “Axena Health is focused on providing evidence-based solutions through both formal clinical trials with world-class academic institutions and published real-world evidence.
  • “Two more positive coverage decisions for the Leva System means more women can access effective, first-line treatment for UI.
  • Highmark BCBS and BCBS of ND have joined Cigna in demonstrating their clear commitment to women’s health.

Stork Club Fertility Outcomes Exceed National Benchmarks With Independent Validation

Retrieved on: 
月曜日, 3月 18, 2024
Milliman, Health, ROI, Conference, The Conference Board, SAN, IVF, Center of excellence, COE, Patient, Child, Stork Club, MD, Club, Booth, Spine, Storey, Reproductive endocrinology and infertility, Birth control

SAN FRANCISCO, March 18, 2024 /PRNewswire/ -- Stork Club, a pioneering enterprise reproductive care benefits solution, announced today that it outperforms national averages on all key performance measures. This leads to significantly fewer IVF cycles, and healthier pregnancies, births, and babies born via IVF compared with the US average. These results, validated by an independent auditor, come after Stork Club launched Performance Guarantees for 100% cost accountability tied to the clinical and financial outcomes provided to employers.Stork Club engaged Milliman, Inc., an independent global leader in actuarial services, to evaluate its approach for comparing its results against national benchmarks. In its evaluation, Milliman actuaries concluded that Stork Club's methodology is appropriate and reasonable for estimating clinical performance differences between the national population and individuals who received care under Stork Club's coverage across six key performance metrics.Stork Club's most recently published outcomes are the following:

Key Points: 
  • These results, validated by an independent auditor, come after Stork Club launched Performance Guarantees for 100% cost accountability tied to the clinical and financial outcomes provided to employers.
  • Stork Club engaged Milliman, Inc. , an independent global leader in actuarial services, to evaluate its approach for comparing its results against national benchmarks.
  • Stork Club helps steer patients to fertility clinics that drive better outcomes while still giving patients the flexibility to select a provider of their choice.
  • Stork Club collects outcomes data directly from its providers via proprietary software to enable real-time proactive care management for its patients.

Axena Health study shows incontinence is a major burden for women in Kenya and Nigeria

Retrieved on: 
金曜日, 3月 8, 2024
General Health, Health, Women, Consumer, UI, Woman, Radar, Mother, Education, Interest, Quality of life, Excess post-exercise oxygen consumption, Female, Urinary incontinence, Prevalence, Storey, Incontinence, Social stigma, Global Health, Family, MPH, DPT, Fistula, PFMT, Workforce, Research

Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, unveiled the findings from a landmark study to understand the impact of urinary incontinence (UI) on women in sub-Saharan Africa.

Key Points: 
  • Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, unveiled the findings from a landmark study to understand the impact of urinary incontinence (UI) on women in sub-Saharan Africa.
  • Through conversations, focus groups and quantitative surveys, women and clinicians expressed a strong desire for education and treatment.
  • Axena Health will conduct a second study in Nigeria to test the feasibility of implementing clinic-based treatment that leverages Leva’s technology.
  • “We believe this is the first large-scale qualitative study to document the significant burden of incontinence among women in Kenya and Nigeria,” said Oliver Muchiri, co-author of the report and Practice Lead, Service and Systems Design Unit at ThinkPlace Kenya.

Axena Health Commends New Study Showing the Leva System’s Long-term Treatment Efficacy for Female Urinary Incontinence

Retrieved on: 
火曜日, 1月 23, 2024
Women, Seniors, Physical Therapy, Health, FDA, Medical Devices, Health Technology, Consumer, Woman, Patient, Reproductive biology, Associate, MD, The Green Journal, Overactive bladder, Female, RCT, Harvard Medical School, Manager, FACS, PFMT, Urinary incontinence, University, Medicine, Quality of life, Risk, Incontinence, Food, Journal, FACOG, Storey, UI, Hospital, ACOG, Massachusetts General Hospital, American College, Birth control

Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, announced today that leading pelvic health researchers have published a new study demonstrating the Leva® Pelvic Health System’s long-term treatment efficacy for female urinary incontinence (UI).

Key Points: 
  • Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, announced today that leading pelvic health researchers have published a new study demonstrating the Leva® Pelvic Health System’s long-term treatment efficacy for female urinary incontinence (UI).
  • “Two years of data showing that UI symptom relief endures following eight weeks of guided-PFMT offers compelling evidence that women can access first-line, conservative treatment successfully.
  • “This newest published study offers powerful evidence that women can access first-line treatment successfully, and that this treatment has a lasting effect.
  • “Pelvic floor muscle training is globally recommended first-line treatment for urinary incontinence,” said Eileen Maus, CEO of Axena Health.

Child care advocates and Toronto City Councillors to hold press conference

Retrieved on: 
火曜日, 11月 28, 2023
Public Policy, Government, General Health, Health, Children, Family, Baby, Maternity, Labor, Consumer, CUPE, Storey, Second, Toronto City Hall, Committee, Child care, Ontario Coalition Against Poverty, Town hall

Toronto Community for Better Child Care, Ontario Coalition for Better Child Care, CUPE 2484 Toronto Child Care Workers, City Councillors.

Key Points: 
  • Toronto Community for Better Child Care, Ontario Coalition for Better Child Care, CUPE 2484 Toronto Child Care Workers, City Councillors.
  • Now we need to focus on solutions,” said Carolyn Ferns, Policy Coordinator for the Ontario Coalition for Better Child Care.
  • “It costs more to build child care spaces in Toronto.
  • Those hurdles can’t stop us from increasing the supply of quality, public and non-profit child care services that families deserve.

Ault Alliance Enters Into an Agreement for a Financing of up to $50 Million

Retrieved on: 
火曜日, 11月 7, 2023
Technology, Finance, Fintech, Other Technology, Professional Services, Business, Blockchain, Data Management, Cryptocurrency, Artificial Intelligence, Bitcoin, Sale, NYSE, Storey, Ault, Warrant, Exercise, Common stock, Common, AAI, Conversion, Agreement, Funding, Security (finance)

Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company (“AAI” or the “Company”), announced today that it has entered into a Securities Purchase Agreement (the “Agreement”) providing for up to $50 million of financing (the “Financing”) from Ault & Company, Inc., a related party (“A&C”).

Key Points: 
  • Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company (“AAI” or the “Company”), announced today that it has entered into a Securities Purchase Agreement (the “Agreement”) providing for up to $50 million of financing (the “Financing”) from Ault & Company, Inc., a related party (“A&C”).
  • Pursuant to the Agreement, AAI has agreed to issue and sell to A&C up to $50 million in shares of Series C Convertible Preferred Stock (the “Preferred Shares”).
  • Each is a vital component of our collective success," said Milton "Todd" Ault III, Executive Chairman of Ault Alliance and Chairman & CEO of A&C.
  • The Agreement provides for several closings through December 29, 2023, though such dates may be extended by A&C as set forth in the Agreement.